Low magnesium link to PPIs prompts safety update

THE TGA has issued a medicines safety update for PPIs, warning of the risk to patients of hypomagnesaemia and other life-threatening events, pointing to an advisory released by the US Food and Drug Administration in March.

“A recent international safety advisory has warned of a potential association between prolonged use of PPIs and serious hypomagnesaemia-related adverse events such as tetany, seizures, delirium and cardiac arrhythmias,” the TGA said.

 “While this occurs rarely, prescribers should be vigilant to PPI-associated hypomagnesaemia [and] patients presenting